Логин: Пароль: ?
 
Продукты питания Ткань, одежда, обувь, постельное белье, текстиль Строительные материалы Бумага, пластик, промтовары Биотопливо Продукция для сельского хозяйства, зоотовары Косметика, средства гигиены Медицинские товары и препараты, лекарства Иное

 

 

 

 

 

 

 

Новости/Аналитика

Medical cannabis sales volumes in Germany fall

24.09.2020

Among the major insurers that have reimbursed the cost of “hemp prescriptions”, the total number of applications approved since 2017 is less than 0.1% of the population insured by them. The only exception is Barmer Insurance, which approved bids for 0.13% of clients served. At the same time, a study by experts from the information and consulting company Hemp Consulting suggests that the number of patients who prefer to use pharmacological preparations based on the therapeutic properties of a plant varies in different countries within the maximum possible range of 0.3% - 0.4 % of the total population.

Foreign pharmaceutical companies that are trying to impose on the government of our country the concept that there is no alternative to the use of pharmacological preparations based on the therapeutic properties of cannabis, for the most part, appeal with unfounded statements and unconfirmed data. In particular, the question is constantly raised about the potential of the market for the use of “hemp pharmacological preparations”, which allegedly require from 2 to 2.5 million of the population of our country. On the pages of the specialized electronic edition of Ukrainian cannabis growers, attention has already been focused on the global trend of a rapid increase in the number of patients in countries where the possibility of using pharmacological preparations based on the therapeutic properties of the hemp plant for the first 2-3 years is regulated. Further, the market saturation and its gradual stagnation occurs if the citizens of the above countries have the opportunity to use not only the properties of the hemp plant medicinally, but also use it as food / dietary supplements or use leaves and inflorescences as nutraceuticals. In order to evaluate the research of specialists of the information and analytical company Hemp Consulting, who claim that the maximum number of patients interested in using “hemp pharmacological preparations” does not exceed 180-200 thousand people in Ukraine, we will analyze open data published by German government agencies. Moreover, this information will be interesting due to the fact that in Germany the cost of “hemp pharmacological” drugs is compensated with the help of insurance medicine.  

Reimbursement of "insurance prescriptions" for cannabinoid-rich goods in Germany 

According to the official data published for the second quarter of 2020, insurance coverage in Germany for the use of medical cannabis fell for the first time since the start of the current medical program, which was initiated in March 2017. Information from the German National Association of Compulsory Health Insurance Funds (GKV-Spitzenverband) indicates that in the second quarter of 2020, the total reimbursement of medical cannabis and medicinal products based on the therapeutic properties of the plant decreased by 6% compared to the first quarter of 2020. of the year. 

It should be borne in mind that the number of prescriptions “canceled by insurance” has not increased despite the fact that prices have significantly decreased throughout the year. In previous quarters, the average prescription check covered by insurance was around € 500, while in the second quarter of 2020 the value dropped to € 454. Sales in April, May and June remained stable at € 12 to € 12.5 million . - i.e. remained at about the same level as in the last months of 2019.

Leaves and buds, which have therapeutic properties, still account for about half of the entire market for medical hemp in Germany. In the second quarter, the number of sales of this product category amounted to 48% compared to 51% in the previous reporting period. The volume of sold extracts increased from 34% to 37% of the total reimbursement of used prescription hemp products. The finished pharmaceutical product category remains stable and accounts for the remaining 15% of the market. At the moment, all imported hemp raw materials, as well as flower extracts or extracts of the full spectrum, are imported to Germany from Canada, the Netherlands, Portugal and more recently Spain.

Less than 0.1% of the population

Among the major insurers that have reimbursed the cost of “hemp prescriptions”, the total number of applications approved since 2017 is less than 0.1% of the population insured by them. The only exception is Barmer Insurance, which approved bids for 0.13% of clients served. At the same time, a study by experts from the information and consulting company Hemp Consulting suggests that the number of patients who prefer to use pharmacological preparations based on the therapeutic properties of a plant varies in different countries within the maximum possible range of 0.3% - 0.4 % of the total population.

Commentary of experts of the Association "Ukrainian technical hemp"

The experience of Germany is interesting not only because it demonstrates the dynamics of the use of medicinal products made on the basis of hemp in the largest European market for consumers of this product. In democratic Germany, foreign companies exporting leaves and inflorescences of a plant or preparations made on its basis are doing everything possible to block the cultivation of "green mass" of a plant rich in therapeutically active substances by German producers in the country itself, starting from 2017. Another fact is that even a decrease in the cost of pharmacological preparations or the leaves and inflorescences of medical cannabis sold through the German pharmacy chains does not lead to an increase in the number of patients using them during the third-fourth quarters of 2019 - the entire 2020 (except for March, when there was a massive purchase of the entire spectrum of products related to the therapeutic properties of cannabis in anticipation of possible supply disruptions due to the coronavirus pandemic).

Separate elements of the research of the information and analytical platform Hemp Consulting, demonstrating the potential volume of the medical cannabis market in our country, as well as the dynamics of the increase in the number of consumers in certain economically developed countries of the world up to the moment of “market saturation” will be demonstrated during the round table “ Experience of using therapeutic elements technical hemp as a raw material for food products, cosmetics, biologically active or feed additives ”, which will be held within the 5th course of training for students of the“ Hemp University ” held on October 13-14 at the National University of Bioresources and Nature Management of Ukraine.

Потенциал национального рынка каннабиноидных косметических препаратов
17.01.2024

В Украине потребитель готов для выведения на рынок линейки национальной профессиональной CBD косметической продукции

Объявления
Все объявления »
 
 

facebook

telegram

twitter